New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 3, 2013
08:40 EDTOMEDOncoMed reports Q2 EPS ($8.83), may not compare to consensus (2c)
Reports Q2 revenue $2.9M, may not compare to consensus $8.31M. The decrease in revenue vs. $7.5M in 2Q12 was mainly a result of timing of a $5M milestone payment that was achieved in the 2Q12, offset by $400K in collaboration revenue recognized in the 2Q13 related to the amortization of a payment from Bayer received in August 2012.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 13, 2015
05:52 EDTOMEDOncoMed pipeline 'dramatically' undervalued, says Piper Jaffray
Following the company's Q4 results, Piper Jaffray says it views OncoMed's clinical pipeline as "dramatically" undervalued. Piper notes the company ended 2014 with $232M in cash and guided to end 2015 with greater than $120M. It reiterates an Overweight rating on the stock with a $43 price target.
March 12, 2015
16:13 EDTOMEDOncoMed sees 2015 cash expenses $100M-$110M
Subscribe for More Information
16:11 EDTOMEDOncoMed reports Q4 EPS (50c), may not compare to consensus (27c)
Reports Q4 revenue $8.5M, may not compare to consensus $18.24M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use